Etudes cliniques

SELECT - Semaglutide effects on cardiovascular outcomes in people with overweight or obesity; a randomised, double-blind, parallel group, placebo-controlled trial comparing semaglutide 2.4 mg with semaglutide placebo both administered s.c. once-weekly in subjects with established CV disease and overweight or obesity

Differential analysis of uric acid metabolism, endothelial function, oxidative stress and cardiovascular parameters in vegans and omnivores.

A Phase 2, double-blind, placebo-controlled, randomized study to compare the efficacy and safety of sotatercept (ACE-011) versus placebo when added to standard of care for the treatment of pulmonary arterial hypertension (PAH)

A multi-center, randomized, double-blind, phase IV clinical trial on the diuretic effects of Acetazolamide (Diamox ®) in patients with Decompensated heart failure and Volume OveRload

A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fraction (HFrEF)

Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation – in atrial fibrillation (ENVISAGE-TAVI-AF)

A randomised controlled trial of Rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease (COMPASS- Cardiovascular OutcoMes for People using Anticoagulation StrategieS) - Long-Term Open-Label Extension (LTOLE).

Fluid challenge test for the differential diagnosis of pulmonary hypertension: evaluation of an invasive approach and definition of limits of normal

EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care DA VINCI